(Acquisition news soon IMO- first mover advantage)
What recent news would you like to highlight to investors attending?
Continued high grade exploration results from Macy prospects and greenfields targets
Completion of Scoping Study on Macy deposit
Commencement of mining at Macy and initial revenue generation
Further resource delineation at Aisha and other prospects
Expanded mining program
Expected project acquisitions taking advantage of first mover advantage in Nigeria
What are your key goals for the next 3, 6 and 12 months?
3 Months:
Continued high grade exploration results
Aisha prospect Resource drillout
Additional exploration across 500km2 of tenements
6 Months:
Commencement of Mining
First sales and concentrate shipment
First revenues
12 Months:
Establish Resources over 1mt
Acquisition of other Nigerian projects
Expansion of revenue generation
What do you see as the key risks and challenges facing your company at the moment and how are you overcoming these?
Key Risks
Nigeria – strong joint venture partners. Continue community and Ministerial engagement programs. Be a good corporate citizen in country.
Commodity Prices – diversify metals exposure through acquisition
In a sentence, what do you think makes your company such a compelling investment?
Symbol Mining is unique given ultra high grades at shallow depths, where the mineralised ore is non-disseminated; therefore a high grade concentrate can be delivered at low cost with limited processing. Symbol provides an exposure to base metal production along with exploration upside over a large tenement package in a frontier mining jurisdiction
- Forums
- ASX - By Stock
- SL1
- Ann: Symbol Executes Offtake Agreement and Loan Facility
Ann: Symbol Executes Offtake Agreement and Loan Facility, page-37
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SL1 (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online